Loading resource…

Suchira Gallage, Olivier Govaere, Quentin M. Anstee, Gerald I. Shulman, Frank Tacke, Mathias Heikenwalder
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease that poses risks for cirrhosis, hepatocellular carcinoma, and various extrahepatic complications. Recent clinical trials have introduced new pharmacological treatments, including THR β agonists and GLP-1R agonists, which provide options for non-cirrhotic patients. The document emphasizes the heterogeneity of MASH and the importance of tailored treatment strategies that consider distinct disease subsets and their associated risks.
No account needed